Correlation between hematological parameters and outcome in patients with locally advanced cervical cancer treated by concomitant chemoradiotherapy

Autor: Annelore Barbeaux, Laurence Seidel, Christine Gennigens, Johanne Hermesse, Guy Jerusalem, Frédéric Kridelka, Adelin Albert, Frederic Forget, Marjolein De Cuypere
Jazyk: angličtina
Rok vydání: 2020
Předmět:
0301 basic medicine
Cancer Research
Time Factors
Neutrophils
medicine.medical_treatment
Uterine Cervical Neoplasms
Gastroenterology
chemoradiotherapy
Hemoglobins
0302 clinical medicine
Leukocytes
locally advanced cervical cancer
Original Research
Cervical cancer
Aged
80 and over
neutrophil
Middle Aged
lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
medicine.anatomical_structure
Treatment Outcome
Oncology
030220 oncology & carcinogenesis
Carcinoma
Squamous Cell
Disease Progression
Female
white blood cell
Erythrocyte Transfusion
Adjuvant
medicine.drug
Adult
medicine.medical_specialty
Antineoplastic Agents
Adenocarcinoma
lcsh:RC254-282
03 medical and health sciences
Internal medicine
White blood cell
medicine
Humans
Radiology
Nuclear Medicine and imaging
transfusion
Aged
Neoplasm Staging
Retrospective Studies
Cisplatin
Proportional hazards model
business.industry
Clinical Cancer Research
hemoglobin
medicine.disease
030104 developmental biology
Concomitant
Hemoglobin
Dose Fractionation
Radiation
Radiotherapy
Intensity-Modulated
Neoplasm Recurrence
Local
Radiotherapy
Conformal
business
Chemoradiotherapy
Biomarkers
Zdroj: Cancer Medicine
Cancer Medicine, Vol 9, Iss 22, Pp 8432-8443 (2020)
ISSN: 2045-7634
Popis: Background Hemoglobin (Hb), white blood cell (WBC), and polymorphonuclear neutrophil (PMN) blood counts may be correlated with outcomes in patients with locally advanced cervical cancer. Methods Hb, WBC, and PMN counts were measured at diagnosis and during concomitant cisplatin‐based chemoradiotherapy (CCRT) in a retrospective sample of 103 patients between 2010 and 2017. Red blood cell (RBC) transfusions were also recorded. The associations between hematological variables and patient overall survival (OS) and recurrence‐free survival (RFS) were assessed by Cox regression models. Results The 3‐year OS and RFS rates were 81.4% and 76.8%, respectively. In addition to tumor size and smoking, OS and RFS were found to be significantly associated with changes in WBC and PMN counts from the first to the last cisplatin cycle. Hb count throughout the treatment and RBC transfusions were not predictive of outcome. Conclusions This study found no association between Hb count or RBC transfusions and outcome. The daily practice of maintaining the Hb count above 12 g/dL during CCRT should be weighed against the potential risks of transfusions. Drops in WBC and PMN counts during treatment positively impacted OS and RFS and could, therefore, serve as biomarkers during CCRT to adapt the follow‐up and consider the need for adjuvant systemic treatments.
In patients with locally advanced cervical cancer. Daily practice of maintaining the Hb count above 12 g/dL during CCRT should be weighed against potential risks of transfusions. Drops in WBC and PMN counts during treatment positively impacted OS and RFS
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje